Translational relevance is underscored by human studies showing that pioglitazone treatment reduces hnRNPA2B1 expression in subcutaneous adipose tissue of individuals with type 2 diabetes, with changes in hnRNPA2B1 expression significantly correlating with improvements in insulin sensitivity, lipid metabolism, glycemic control, and body composition [91]. Here, HNRNPA2B1 is linked to type 2 diabetes mellitus.